[Hyperlipoproteinaemia during additional methenolone administration in the treatment of metastasizing carcinoma of the breast].
The effect of additive administration of methenolone oenanthate (Primobolan) on lipid metabolism was studied in 28 menopausal women with metastasizing carcinoma of the breast. In ten women hyperlipoproteinaemia type IIa was demonstrated in the course of treatment, while in two there was hyperlipoproteinaemia type IIb. One of the latter patients had a myocardial infarction in the course of treatment. There was no relationship between the level of hypercholesterolaemia and the methenolone dosage. Nor was it possible to classify the type of cholesterolaemia as a bile stasis syndrome. The hyperlipoproteinaemia regressed in every case once methenolone treatment was discontinued.
D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced; D006938:Hyperlipoproteinemia Type II / Q000139:chemically induced*; D008710:Methenolone / Q000009:adverse effects*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000556:secondary
D008710:Methenolone
Hyperlipoproteinämie bei additiver Behandlung des metastasierenden Mammakarzinoms mit Metenolonönanthat.